Stock Research for CGEN

CGEN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CGEN Stock Chart & Research Data

The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CGEN Due diligence Resources & Stock Charts

The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CGEN Detailed Price Forecast - CNN Money CNN View CGEN Detailed Summary - Google Finance
Yahoo View CGEN Detailed Summary - Yahoo! Finance Zacks View CGEN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CGEN Trends & Analysis - Trade-Ideas Barrons View CGEN Major Holders - Barrons
NASDAQ View CGEN Call Transcripts - NASDAQ Seeking View CGEN Breaking News & Analysis - Seeking Alpha
Spotlight View CGEN Annual Report - CompanySpotlight.com OTC Report View CGEN OTC Short Report - OTCShortReport.com
TradeKing View CGEN Fundamentals - TradeKing Charts View CGEN SEC Filings - Bar Chart
WSJ View Historical Prices for CGEN - The WSJ Morningstar View Performance/Total Return for CGEN - Morningstar
MarketWatch View the Analyst Estimates for CGEN - MarketWatch CNBC View the Earnings History for CGEN - CNBC
StockMarketWatch View the CGEN Earnings - StockMarketWatch MacroAxis View CGEN Buy or Sell Recommendations - MacroAxis
Bullish View the CGEN Bullish Patterns - American Bulls Short Pains View CGEN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CGEN Stock Mentions - StockTwits PennyStocks View CGEN Stock Mentions - PennyStockTweets
Twitter View CGEN Stock Mentions - Twitter Invest Hub View CGEN Investment Forum News - Investor Hub
Yahoo View CGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View CGEN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CGEN - SECform4.com Insider Cow View Insider Transactions for CGEN - Insider Cow
CNBC View CGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CGEN - OTC Markets
Yahoo View Insider Transactions for CGEN - Yahoo! Finance NASDAQ View Institutional Holdings for CGEN - NASDAQ


Stock Charts

FinViz View CGEN Stock Insight & Charts - FinViz.com StockCharts View CGEN Investment Charts - StockCharts.com
BarChart View CGEN Stock Overview & Charts - BarChart Trading View View CGEN User Generated Charts - Trading View




Latest Financial News for CGEN


Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Posted on Monday May 06, 2024

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.


We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
Posted on Monday April 29, 2024

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Compugen...


Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Posted on Thursday April 25, 2024

Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.


Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Posted on Wednesday April 10, 2024

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects' link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for


Stock Market & Investing Books

Enter a stock symbol to view the stock details.